Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Bayer's Precision Medicine Approved in China for NTRK Gene Fusion Cancers

publication date: Apr 15, 2022

Germany’s Bayer announced China approval of Vitrakvi™ (larotrectinib), a precision medicine for adult and pediatric patients who have advanced solid tumors that harbor a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion. Larotrectinib is a first-in-class, highly selective TRK inhibitor. In clinical trials, larotrectinib demonstrated efficacy in more than 20 different solid tumors including lung, thyroid and colorectal cancers. It was also effective in salivary gland cancer and soft tissue sarcomas. According to Bayer, Vitrakvi is the first therapy in China with a tumor-agnostic indication. More details....

Stock Symbols: (XE: BAYN)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital